Back to Search
Start Over
A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation.
- Source :
-
Oncology (Williston Park, N.Y.) [Oncology (Williston Park)] 2024 Jun 10; Vol. 38 (6), pp. 230-231. - Publication Year :
- 2024
-
Abstract
- Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted therapy.
- Subjects :
- Humans
Cyclin-Dependent Kinase 4 genetics
Female
Skin Neoplasms genetics
Skin Neoplasms pathology
Skin Neoplasms drug therapy
Middle Aged
Adenocarcinoma genetics
Adenocarcinoma drug therapy
Adenocarcinoma pathology
Protein Kinase Inhibitors therapeutic use
Cyclin-Dependent Kinase 6 genetics
Cyclin-Dependent Kinase 6 antagonists & inhibitors
Male
Pyridines therapeutic use
Sweat Gland Neoplasms genetics
Sweat Gland Neoplasms pathology
Sweat Gland Neoplasms drug therapy
Piperazines therapeutic use
Mutation
Cyclin-Dependent Kinase Inhibitor p16 genetics
Subjects
Details
- Language :
- English
- ISSN :
- 0890-9091
- Volume :
- 38
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Oncology (Williston Park, N.Y.)
- Publication Type :
- Academic Journal
- Accession number :
- 38899982
- Full Text :
- https://doi.org/10.46883/2024.25921022